Pay in 4 interest-free payments of $6.58 Learn more
Ships within 48 hours · Estimated delivery Sep 7 - Sep 12
Support sustainable weight loss when paired with lifestyle changes
A new pathway to access Wegovy for obesity The Medicare GLP-1 Bridge Program is a nationwide, short-term CMS program designed to cover select weight-management drugs for Medicare Part D beneficiaries Medicare GLP-1 Bridge Program Eligible patients can access all doses of Wegovy pill and pen for only Starting July 1, 2026 1 Medicare GLP-1 Bridge Program eligibility 1 Medication prescribed for weight management, in combination with current and ongoing lifestyle modification consistent with the applicable FDA-approved label Enrolled in a Medicare Part D plan (stand-alone PDP or MA PD), including Special Needs Plans (SNPs), employer/union group waiver plans (EGWPs), Limited Income Newly Eligible Transition (LI NET), and dual-eligible beneficiaries who are enrolled in eligible Part D plan types 18 years of age BMI 35 kg/m 2 or BMI 30 kg/m 2 + 1 or more of the following comorbidities Uncontrolled HTN, HFpEF, CKD Stage 3a, or above or BMI 27 kg/m 2 + 1 or more comorbidities Pre-diabetes, previous stroke/MI, symptomatic PAD Terms apply
These immune cells recognise the beta-glucan and become activated, producing growth factors and cytokines which aid in skin healing
Clinical trials show that 2550% of patients experience nausea during dose escalation, though most side effects resolve within 48 weeks as the body adapts
.png)
US$ 27.89
US$ 25.27
US$ 22.43
US$ 28.83
US$ 25.22
US$ 29.84
